Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 53

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 53
---
 awards will expire on the nine-month anniversary of the date of her separation date from Repare. |

**38

Employment Arrangements with our Named Executive Officers

We have entered into employment agreements with each of our named executive officers. The agreements set forth the terms and conditions of each executive’s employment with us, including base salary, target bonus opportunity, eligibility for employee benefits and severance benefits upon a qualifying termination of employment, and certain non-solicitation and non-competition provisions. Any potential payments and benefits due upon a qualifying termination of employment or a change in control are further described below under “—Potential Payments and Benefits upon Termination or Change in Control.”

The employment of each of our named executive officers may be terminated at any time in accordance with the terms of the respective agreements. In addition, each of our named executive officers has executed a form of our standard proprietary information and inventions agreement. The material terms of each agreement are described below.

Lloyd M. Segal

We entered into an employment agreement with Mr. Segal in January 2018, effective July 1, 2017 in connection with his appointment as our President and Chief Executive Officer. In June 2020, we entered into a new employment agreement with Mr. Segal, which became effective upon the execution of the underwriting agreement for our IPO. Pursuant to his June 2020 employment agreement, Mr. Segal was initially entitled to an annual base salary of $550,000, an annual target bonus with a target amount equal to 50% of his annual base salary and certain severance benefits, as described below under “—Potential Payments and Benefits upon Termination or Change of Control.” Mr. Segal was also eligible for additional equity awards under our equity compensation plans, as may be granted from time to time. In July 2023, we amended Mr. Segal’s June 2020 employment agreement to reflect updated termination of employment and change in control provisions to cover granted RSU awards.

Segal Separation Agreement. On March 31, 2025, Mr. Segal notified the board of directors of his resignation from his positions as President and Chief Executive Officer and as a member of the board, effective April 11, 2025, in order to pursue other opportunities. In connection with his departure from the Company, we and Mr. Segal entered into a separation agreement, dated March 31, 2025 (the “Segal Separation Agreement”). Under the terms of the Segal Separation